HEALTHCARE GLOBAL ENTERPRISES LIMITED HealthCare Global Enterprises Limited Stock
Equities
HCG
INE075I01017
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 370 INR | +1.07% |
|
-2.06% | +1.22% |
| Sales 2024 * | 19.19B 230M | Sales 2025 * | 21.73B 260M | Capitalization | 51.53B 617M |
|---|---|---|---|---|---|
| Net income 2024 * | 398M 4.77M | Net income 2025 * | 928M 11.11M | EV / Sales 2024 * | 2.98 x |
| Net Debt 2024 * | 5.61B 67.16M | Net Debt 2025 * | 4.25B 50.85M | EV / Sales 2025 * | 2.57 x |
| P/E ratio 2024 * |
130
x | P/E ratio 2025 * |
53
x | Employees | 6,136 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 26.94% |
More Fundamentals
* Assessed data
More news
Latest transcript on HealthCare Global Enterprises Limited
| 1 day | +1.07% | ||
| 1 week | -2.06% | ||
| Current month | +9.50% | ||
| 1 month | +8.39% | ||
| 3 months | +1.70% | ||
| 6 months | +0.75% | ||
| Current year | +1.22% |
1 week
360.25
383.30
1 month
326.00383.30
Current year
314.00401.00
1 year
258.00401.00
3 years
161.30401.00
5 years
62.05401.00
10 years
62.05401.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 21-01-31 | |
| Founder | - | 98-03-11 | |
Ruby Ritolia
DFI | Director of Finance/CFO | - | 23-08-20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rajiv P. Maliwal
BRD | Director/Board Member | 63 | 23-05-24 |
| Founder | - | 98-03-11 | |
Amit Soni
BRD | Director/Board Member | 56 | 20-07-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 370 | +1.07% | 163 097 |
| 24-04-16 | 366 | +1.13% | 88,176 |
| 24-04-15 | 362 | -2.56% | 97,261 |
| 24-04-12 | 371.4 | -1.67% | 193,598 |
| 24-04-10 | 377.8 | +0.81% | 357,921 |
Delayed Quote NSE India S.E., April 18, 2024 at 07:43 am EDT
More quotes
HealthCare Global Enterprises Limited is an India-based cancer care provider. The Company is a provider of specialty healthcare focused on cancer and fertility. Under the HCG brand, the Company operates cancer care network in India in terms of the total number of private cancer treatment centers. The Company also provide fertility treatment under its Milann brand. Its Milann fertility centers provide reproductive medicine services, including assisted reproduction, gynecological endoscopy and fertility preservation; and follow a multidisciplinary and technology focused approach to diagnosis and treatment. Under the Triesta brand, it offers oncology diagnostics, biomarker and translational research, and laboratory services. The Company also operates comprehensive cancer care center in Indore, Madhya Pradesh. The Company is also engaged in radiation business in Indore, Madhya Pradesh.
Calendar
2024-05-22
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
370
INR
Average target price
414.1
INR
Spread / Average Target
+11.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.22% | 609M | |
| -12.12% | 86.47B | |
| +9.72% | 82.27B | |
| +10.85% | 29.43B | |
| -12.25% | 16.82B | |
| -5.06% | 15.89B | |
| -8.68% | 14.1B | |
| +1.87% | 12.05B | |
| -30.00% | 12.01B | |
| +20.38% | 11.19B |
- Stock Market
- Equities
- HCG Stock
